Recently 688180.SH, the company's product triprimumab (trade name: Tuoyi ®, product code: JS001) combined with standard chemotherapy as an adjuvant therapy after radical resection of gastric or esophageal gastric and gastric junction adenocarcinoma Phase III clinical study (referred to as "JUPITER-15 study", NCT05180734) has completed the first patient administration.
It is reported that triplixumab is China's first approved marketing of PD-1 as the target of domestic monoclonal antibody drugs, as of the announcement disclosure date, treplelimab has been awarded by the FDA in the field of mucosal melanoma, nasopharyngeal carcinoma, soft tissue sarcoma, esophageal cancer 2 breakthrough therapy identification, 1 fast-track identification, 1 priority review identification and 4 orphan drug qualification certification.
The JUPITER-15 study is a randomized, double-blind, placebo-controlled, international multicenter Phase III clinical study led by Professor Ji Jiafu of Peking University Cancer Hospital, Professor Shen Lin of Peking University Cancer Hospital, and Professor Li Guoxin of Southern Hospital of Southern Medical University, aiming to evaluate the clinical efficacy and safety of triprimumab and placebo-controlled combined standard chemotherapy as a postoperative adjuvant treatment of patients with adenocarcinoma in the gastric or esophageal-gastric junction after radical resection, with a planned enrollment of 680 patients. More than 60 research centers are involved. This is the first large-scale international multi-center Phase III clinical study of adjuvant therapy in the field of stomach cancer with high incidence in China.
This article originated from Zhitong Finance Network